Brief: Ose Immunotherapeutic: Positive Interim Data Analysis From Study Of FR104/VEL-101 Immunotherapy In Renal Transplant
11/12/2023 06:47
Dec 11 (Reuters) - OSE Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS AND NANTES UNIVERSITY HOSPITAL
PRESENT
POSITIVE INTERIM DATA ANALYSIS FROM THE FIRST PHASE 1/2 STUDY
EVALUATING FR104/VEL-101 IMMUNOTHERAPY IN RENAL TRANSPLANT
Source text for Eikon: ID:nBw7WHz0Xa
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO